Fusion Biopsy for Prostate Cancer | Q&A

H. Ballentine Carter

H. Ballentine Carter M.D.
Professor of Urology, Oncology

Dr. Herbert Ballantine Carter is a professor of urology and oncology at the Johns Hopkins School of Medicine. He is an internationally recognized expert in the diagnosis and treatment of prostate disease, both cancerous and non-cancerous. Dr. Carter also serves as the director of adult urology at the Johns Hopkins School of Medicine. Dr. Carter earned his M.D. from Medical University of South Carolina College of Medicine. He completed his residency in urology and surgery ... View full profile

More Information

What kind of information would you like to request?     More Information       Make a Referral

Leave this field empty

Dr. H. Ballentine Carter, professor of urology and oncology, explains the difference between a standard biopsy procedure and a fusion biopsy procedure for prostate cancer.  

To learn more about fusion MRI guided biopsy, please visit our website: hopkinsmedicine.org/urology

Questions Asked:

1. What is the difference between a standard ultrasound guided biopsy and a fusion MRI guided biopsy for prostate cancer? (0:05)
2. Who is the ideal patient for a fusion biopsy procedure? (0:21)
3. What research has the Johns Hopkins Brady Urological Institute done to determine the success of the fusion procedure? (0:42)
4. Why should I refer patients to Johns Hopkins for fusion biopsy procedures? (1:28)